entertainment -WSS

entertainment

author：comprehensive 2025-10-01 00:58:24 - browse：6755

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Doctors increasingly discourage vaping amid mounting health concerns

entertainment

WSS

Biden has enormous polling lead in Democratic primary, despite challenge from RFK Jr.

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Campaign finance charge dropped from case against Sam Bankman

New chief aims to remake Sanofi Genzyme

Philippine ferry was overloaded when it flipped over, leaving 27 dead, official says

American TikTok star stuck in Dubai for months following rental car altercation

focus

entertainment

entertainment

Psychedelics group wrestles with new pharma identity

Why Marc Tessier

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Judge orders hearing on Trump's motion to disqualify Fulton County DA

United colonoscopy coverage change 'may cost lives,' doctors say

A pollution tax on older cars can be extended to London's suburbs after a British court ruling

In age of alternative facts, a scholarly course on calling out crap

'The View' co

How one medical school became remarkably diverse

Washington Commanders' Dan Snyder ordered to pay NFL $60M following investigation

hotspot

Trump Organization, Michael Cohen agree to settle million

Hey, doctors: Don't be no

What is the Turing Test that determines if computers can think?

A former Republican legislative candidate has been charged for his role in the US Capitol riot

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

A new deal aims to ramp up use of AI in rehab care decisions

Wikipedia

entertainment

focus

knowledge